ESMO 2018 | SOLO-1: practice changing results for advanced ovarian cancer
SOLO-1 (NCT01844986) is the first Phase III study of a maintenance PARP inhibitor in the frontline setting in advanced ovarian cancer. Susana Banerjee, MBBS, PhD, FRCP, from the Royal Marsden NHS Foundation Trust, London, UK, describes the practice changing results from this study, presented at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany. Patients with BRCA mutated ovarian cancer who had previously received first-line platinum-based chemotherapy were given olaparib as a monotherapy. These women had a clinically significant benefit with regards to overall survival.
Get great new content delivered to your inboxSign up